Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Objective: There are significant inequities in colorectal cancer (CRC) screening and outcomes. Via literature review, we assessed CRC screening rates for the vulnerable populations served by free clinics.
Methods: A systematic review was conducted for publications on CRC screening in free clinics. Outcomes included CRC screening characteristics, population demographics, and limitations. A methodological quality assessment was completed.
Results: Out of 63 references, six studies were included, representing 8,844 participants. Black or Hispanic participants were the plurality in all but one study. All participants were uninsured. Median CRC screening rate was 48.4% (range 6.6-78.9%). Screening methods included colonoscopy, fecal occult blood test, flexible sigmoidoscopy, and fecal immunochemical test. Clinics offering only one screening method had a mean screening rate of 7.2% while those with multiple methods had a screening rate of 65.4%.
Conclusion: Access to multiple CRC screening modalities correlates with higher screening rates in free clinics. More work is needed to increase CRC screening in free clinics.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
CD160 dictates anti-PD-1 immunotherapy resistance by regulating CD8 T cell exhaustion in colorectal cancer.
Nat Cell Biol
September 2025
NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University, Harbin, China.
The colon exhibits higher propensity for tumour development than ileum. However, the role of immune microenvironment differences in driving this disparity remains unclear. Here, by comparing paired ileum and colon samples from patients with colorectal cancer (CRC) and healthy donors, we identified ileum-enriched CD160CD8 T cells with previously unrecognized characteristics, including resistance to terminal exhaustion and strong clonal expansion.
View Article and Find Full Text PDFTerritorial equity assessment within a colorectal cancer screening program: usefulness of colonoscopy quality indicators.
Gastroenterol Hepatol
September 2025
Department of Gastroenterology, Hospital Clinic of Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Centro de Investigación Biomédica en Red en Enfermedades Hepáticas y Digestivas (CIBERehd), University of Barcelona. Barcelona, Catalonia, Spain. Electronic address:
Objective: The primary goal of a public health system is to ensure universal access to high-quality medical care. However, disparities in health outcomes have been observed across socio-demographic groups, some of them potentially related to their geographical location. To assess territorial equity, the Catalan Colorectal Cancer Screening Program was used, focusing on the adenoma detection rate (ADR) endoscopists.
View Article and Find Full Text PDFRisk of colorectal cancer and participation in fecal immunochemical test-based screening.
Public Health
September 2025
Department of Public Health, Erasmus MC University Medical Center, Rotterdam, the Netherlands.
Objectives: Participation rates in fecal immunochemical test (FIT)-based colorectal cancer (CRC) screening differ across socio-demographic subgroups. The largest health gains could be achieved in subgroups with low participation rates and high risk of CRC. We investigated the CRC risk within different socio-demographic subgroups with low participation in the Dutch CRC screening program.
View Article and Find Full Text PDFWhole transcriptome analysis identifies fusion as a novel biomarker in metastatic colorectal cancer.
Cancer Pathog Ther
September 2025
Department of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad 211004, India.
Background: Colorectal cancer (CRC) is a complex, heterogeneous disease characterized by frequent relapses and metastasis. Previous studies have reported that the invasion and progression of CRC in several cases can be controlled by targeting fusion genes. This study aimed to screen for potent fusion transcripts as potential molecular biomarkers and therapeutic targets for metastatic CRC (mCRC) using an approach.
View Article and Find Full Text PDFBiomarkers for colorectal cancer detection: An insight into colorectal cancer and FDA-approved biomarkers.
Bioimpacts
August 2025
Department of Pharmacognosy, Faculty of Pharmacy, Gazi University, Ankara 06330, Türkiye.
Colorectal cancer (CRC) constitutes a significant global health challenge, accounting for a considerable proportion of cancer cases and associated mortality. Projections indicate a potential increase in new cases by 2040, attributed to demographic factors such as aging and population growth. Although advancements in the understanding of CRC pathophysiology have broadened treatment options, challenges such as drug resistance and adverse effects persist, highlighting the necessity for enhanced diagnostic methodologies.
View Article and Find Full Text PDF